See more : Proto Labs, Inc. (0KRR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Medicine Man Technologies, Inc. (SHWZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicine Man Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Isonics Corporation (ISON) Income Statement Analysis – Financial Results
- Industrias CH, S. A. B. de C. V. (ICHB.MX) Income Statement Analysis – Financial Results
- Datasonic Group Berhad (5216.KL) Income Statement Analysis – Financial Results
- Polestar Automotive Holding UK PLC (PSNY) Income Statement Analysis – Financial Results
- Ramelius Resources Limited (RMS.AX) Income Statement Analysis – Financial Results
Medicine Man Technologies, Inc. (SHWZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.schwazze.com
About Medicine Man Technologies, Inc.
Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and Colorado; and 10 medical retail cannabis dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.45M | 159.38M | 108.42M | 24.00M | 10.62M | 7.92M | 3.53M | 631.46K | 835.78K | 251.89K |
| Cost of Revenue | 96.42M | 74.35M | 59.07M | 17.23M | 7.62M | 2.58M | 1.30M | 462.18K | 209.75K | 72.00K |
| Gross Profit | 76.02M | 85.03M | 49.35M | 6.77M | 3.00M | 5.35M | 2.23M | 169.27K | 626.03K | 179.89K |
| Gross Profit Ratio | 44.09% | 53.35% | 45.52% | 28.23% | 28.27% | 67.47% | 63.10% | 26.81% | 74.90% | 71.42% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.40M | 7.13M | 1.01M | 519.88K | 193.15K |
| Selling & Marketing | 0.00 | -34.77M | 0.00 | 0.00 | 0.00 | 291.71K | 183.78K | 311.52K | 16.00K | 15.50K |
| SG&A | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Other Expenses | 1.80M | 24.14K | 22.33M | 32.62K | 11.99M | 1.37M | -70.04K | 165.02K | 0.00 | 0.00 |
| Operating Expenses | 72.73M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Cost & Expenses | 169.16M | 138.51M | 98.01M | 46.90M | 24.08M | 7.27M | 8.62M | 1.78M | 745.62K | 280.64K |
| Interest Income | 0.00 | 30.14M | 7.01M | 41.46K | 31.91K | 30.00K | 30.00K | 14.02K | 8.07K | 3.12K |
| Interest Expense | 32.07M | 30.14M | 7.01M | 41.46K | 192.11K | 0.00 | 86.02K | 125.16K | 0.00 | 1.18K |
| Depreciation & Amortization | 20.93M | 11.55M | 8.58M | 476.59K | 61.71K | 81.96K | 63.74K | 17.37K | 6.62K | 561.00 |
| EBITDA | 37.52M | 38.12M | 3.47M | -19.80M | -13.55M | 1.61M | -5.23M | -1.42M | 96.77K | -30.40K |
| EBITDA Ratio | 21.76% | 20.02% | 3.20% | -104.26% | -89.16% | 9.64% | -143.42% | -177.48% | 11.58% | -9.95% |
| Operating Income | 3.29M | 20.89M | -5.11M | -22.90M | -13.46M | 2.17M | -5.24M | -1.15M | 90.15K | -28.75K |
| Operating Income Ratio | 1.91% | 13.11% | -4.71% | -95.43% | -126.80% | 27.39% | -148.34% | -182.45% | 10.79% | -11.41% |
| Total Other Income/Expenses | -18.10M | -16.42M | 8.51M | 2.59M | -476.76K | -638.50K | -145.22K | -312.18K | 8.07K | 1.94K |
| Income Before Tax | -14.81M | -3.57M | 18.92M | -20.32M | -17.56M | 1.53M | -5.38M | -1.46M | 98.22K | -26.81K |
| Income Before Tax Ratio | -8.59% | -2.24% | 17.45% | -84.65% | -165.36% | 19.33% | -152.46% | -231.89% | 11.75% | -10.64% |
| Income Tax Expense | 19.74M | 14.90M | 4.40M | -899.11K | -582.93K | 582.93K | 15.98K | 125.16K | 12.48K | 3.14K |
| Net Income | -34.55M | -18.47M | 14.52M | -19.42M | -16.98M | 948.92K | -5.38M | -1.46M | 85.75K | -29.95K |
| Net Income Ratio | -20.03% | -11.59% | 13.39% | -80.90% | -159.87% | 11.97% | -152.46% | -231.89% | 10.26% | -11.89% |
| EPS | -0.26 | -0.34 | 0.17 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| EPS Diluted | -0.26 | -0.34 | -0.06 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 64.54M | 53.64M | 43.34M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.84M |
| Weighted Avg Shares Out (Dil) | 64.54M | 53.64M | 101.37M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.97M |
Schwazze Provides Update on Delayed Filings
Medicine Man Technologies, Inc. (SHWZ) Q2 2024 Earnings Call Transcript
Schwazze Sets Second Quarter 2024 Conference Call for August 13, 2024 at 5:00 p.m. ET
Schwazze Announces Restructuring of February 2025 Debt Obligations
7 Cannabis Stocks to Sell in July Before They Crash & Burn
Schwazze Announces Transition to OTC Expert Market and Provides Update on Delayed Filing
Schwazze Announces Grand Opening of its 35th New Mexico Dispensary in Bernalillo
Medicine Man Technologies, Inc. (SHWZ) Q1 2024 Earnings Call Transcript
Schwazze Announces First Quarter 2024 Financial Results
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
Source: https://incomestatements.info
Category: Stock Reports